FUNDACION PARA LA INVESTIGACION BIOMEDICA DEL HOSPITAL UNIVERSITARIO PUERTA DE HIERRO-MAJADAHONDA

Their core work

This is the biomedical research foundation of Hospital Universitario Puerta de Hierro, a major public teaching hospital near Madrid. They contribute clinical expertise, patient cohorts, and real-world medical data to European research consortia — particularly in orthopedic regenerative medicine and oncology follow-up care. Their role is typically as a clinical site providing patient access, medical validation, and health data for multi-centre trials and data-driven health platforms. They bridge the gap between laboratory research and hospital-based clinical application.

What they specialise in

How they've shifted over time

Their early H2020 involvement (2017) centred on regenerative medicine — specifically bone marrow stem cell therapies and multi-centre clinical trials for orthopedic conditions. By 2018-2020, the focus shifted decisively toward data-intensive health applications: precision medicine platforms, secure health data exchange, and AI-driven cancer survivorship care. This mirrors the broader hospital sector trend of moving from traditional clinical trials toward digital health and AI-assisted patient management.

Moving toward AI and data science applications in oncology follow-up, making them a relevant clinical partner for digital health and cancer informatics projects.

How they like to work

They participate exclusively as a third party — providing clinical infrastructure, patient data, and medical expertise to consortia led by others. This is characteristic of hospital research foundations that contribute real-world clinical validation rather than leading project design. With 50 unique partners across 14 countries from just 4 projects, they integrate into large, diverse consortia and are comfortable operating within complex multi-site research networks.

Connected to 50 unique partners across 14 countries through large RIA consortia. Their network spans broadly across Europe, reflecting the multi-centre clinical trial and health data integration projects they contribute to.

What sets them apart

As a major Madrid-area university hospital foundation, they offer something many research institutes cannot: direct access to diverse patient populations, clinical workflows, and real hospital data in a controlled, ethics-approved environment. For any consortium needing a Spanish clinical site with experience in both traditional multi-centre trials and modern health data platforms, they are a proven third-party contributor. Their dual track record in regenerative medicine trials and digital health data projects makes them versatile across clinical research domains.

Highlights from their portfolio

• ORTHOUNION
  Randomized clinical trial using regulatory-approved stem cell therapy for bone conditions — represents their strongest clinical trial expertise.
• CLARIFY
  Applies AI to cancer survivorship follow-up across breast, lung cancer, and lymphoma — signals their move into digital oncology and long-term patient monitoring.